NovaBay Pharmaceuticals to Showcase its Full Line of Avenova Eyecare Products at the 126th Annual American Optometric Association Congress

EMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that it will showcase its Avenova^®-branded eyecare products at the 126^th Annual American Optometric Association (AOA) Congress & 55^th Annual American Optometric Student Association (AOSA) Conference: Optometry’s Meeting^® being held June 21-24, 2023 at the Walter E. Washington Convention Center in Washington, D.C. The full line of Avenova dry eye products will be displayed at booth #821 in exhibition hall D&E.

“We invite conference attendees to learn about our extensive line of evidence-led, differentiated and highly effective Avenova-branded products to manage the multifactorial and complex issue of chronic dry eye,” said Justin Hall, NovaBay CEO. “Through our physician-dispensed channel, we make our superior-quality products available for resale by eyecare professionals to their patients. Conference attendees can stop by our booth to discover our new products, sample the full line of Avenova products and take advantage of exclusive AOA conference specials.”

NovaBay offers best-in-class Avenova-branded products for each step of the standard dry-eye treatment regimen, including Avenova spray, the No. 1 doctor-recommended lid and lash cleanser, lubricating eye drops for instant relief, a warm eye compress to soothe, an antioxidant-rich dietary supplement with omega-3 oils and the i-Chek to monitor physical eyelid health. Eyecare professionals interested in learning more about the Avenova physician-dispensed program should email sales@novabay.com or call 510-899-8841.

About Optometry’s Meeting

With expert-led continuing education and professional development (CEE/TQ, AOA CE hours, CPC and COPE credit) available for doctors, paraoptometrics and students, Optometry’s Meeting delivers education that supports every member of the care team. From courses focused on office-based surgical skills and procedures to practical guidance on everything from building a medical contact lens practice to financially preparing for every stage of a career, Optometry’s Meeting is packed with discovery, interdisciplinary collaboration and experiential opportunities. Like no other meeting, Optometry’s Meeting gives every industry professional the unprecedented opportunity to effect lasting change in the profession and make the AOA a stronger, more effective advocate for the quality eye health and vision care services for patients.

About NovaBay Pharmaceuticals, Inc.:

NovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare and skincare products. NovaBay’s leading product, Avenova^® Antimicrobial Lid & Lash Solution, is often prescribed by eyecare professionals for blepharitis and dry-eye disease and is also available directly to eyecare consumers through online distribution channels such as Amazon. DERMAdoctor^® offers more than 30 dermatologist-developed skincare products through the DERMAdoctor website, well-known traditional and digital beauty retailers, and international distributors. NovaBay also manufactures and sells effective, yet gentle and non-irritating wound care products. The PhaseOne^® brand is distributed through commercial partners in the U.S. for professional use only, and the NeutroPhase^® brand is distributed in China by Pioneer Pharma (Hong Kong) Company Ltd.

NovaBay Pharmaceuticals Forward-Looking Statements

Except for historical information herein, matters set forth in this press release may be forward looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial progress and future financial performance of NovaBay Pharmaceuticals, Inc. This release contains forward-looking statements that are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding our business strategies, current partnerships, marketing efforts, and any future revenue that may result from such partnerships and related marketing initiatives, as well as generally the Company’s expected future financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to the size of the potential market for our products, the possibility that the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, and revenues will not be sufficient to meet the Company’s cash needs. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-Q/K filings and Registration Statement on Form S-1 filing with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

Socialize and Stay Informed on NovaBay’s Progress

Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Visit NovaBay’s Website

Avenova Purchasing Information

For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com
Avenova.com

DERMAdoctor Purchasing Information

For DERMAdoctor purchasing information:
Please call 877-337-6237 or email service@dermadoctor.com
DERMAdoctor.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20230620521505/en/